1: McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol 2018;14:1-2. http://doi.org/10.1186/s13223-018-0290-5

2: Netea MG, Schlitzer A, Placek K, Joosten LA, Schultze JL. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. Cell Host Microbe 2019;25(1):13-26. http://doi.org/10.1016/j.chom.2018.12.006

3: Le Deist F, Moshous D, Villa A, Al-Herz W, Roifman CM, Fischer A, et al. Combined T-and B-Cell immunodeficiencies. In: Primary immunodeficiency diseases: definition, diagnosis, and management. Berlin, Heidelberg: Springer Berlin 2016:pp.83-182. https://doi.org/10.1007/978-3-662-52909-6_2

4. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015;136(5):1186-205. http://doi.org/10.1016/j.jaci.2015.04.049

5. Li XC. A new VISTA on kidney fibrosis. Am J Transplant 2022;22(5):1287. https://doi.org/10.1111/ajt.16656

6. Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, et al. Immunoregulatory functions of VISTA. Immunol Rev 2017;276(1):66-79. http://doi.org/10.1111/imr.12525

7. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019;18:1-4. http://doi.org/10.1186/s12943-019-1091-2

8. Azuma M. Co-signal molecules in T-cell activation: historical overview and perspective. Springer Singapore; 2019. http://doi.org/10.1007/978-981-32-9717-3_1

9. Ohno T, Zhang C, Kondo Y, Kang S, Furusawa E, Tsuchiya K, et al. The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses. Int Immunol 2018;30(1):3-11. http://doi.org/10.1093/intimm/dxx070

10. Tagliamento M, Agostinetto E, Borea R, Brandão M, Poggio F, Addeo A, et al. VISTA: a promising target for cancer immunotherapy? Immunotarget Ther 2021:185-200. http://doi.org/10.2147/ITT.S260429

11. Zheng M, Zhang Z, Yu L, Wang Z, Dong Y, Tong A, et al. Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection. Front Immunol 2023;14:1194421. http://doi.org/10.3389/fimmu.2023.1194421

12. Salami F, Fekrvand S, Yazdani R, Shahkarami S, Azizi G, Bagheri Y, et al. Evaluation of expression of LRBA and CTLA-4 proteins in common variable immunodeficiency patients. Immunol Invest 2022;51(2):381-94. http://doi.org/10.1080/08820139.2020.1833029

13. Shashaani N, Chavoshzadeh Z, Ghasemi L, Ghotbabadi SH, Shiari S, Sharafian S, et al. Immunodeficiency due to a novel variant in PIK3CD: a case report. Pediatr Rheumatol 2023;21(1):71. http://doi.org/10.1186/s12969-023-00859-y

14. Gámez-Díaz L, Grimbacher B. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes. Biomed J 2021;44(4):400-11. https://doi.org/10.1016/j.bj.2021.04.005

15. Nishizaki D, Kurzrock R, Miyashita H, Adashek JJ, Lee S, Nikanjam M, et al.

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open 2024;9(4):102942. http://doi.org/10.1016/j.esmoop.2024.102942

16. Muñoz Perez N, Pensabene JM, Galbo PM Jr., Sadeghipour N, Xiu J, Moziak K, et al. VISTA emerges as a promising target against immune evasion mechanisms in medulloblastoma. Cancers 2024;16(15):2629. http://doi.org/10.3390/cancers16152629

17. Wang J, Wu G, Manick B, Hernandez VJ, Ren M, Christian E, et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology 2019;156(1):74-85. http://doi.org/10.1111/imm.13001